Komori
StemRIM (4599) · TargetRestatedLatest Share Issuance and Disposal (2026-09-09): "Advanced"

Recruiting outstanding research personnel

First written in FY2019. 3 of 7 entries say "Advanced", first in FY2020. Latest entry: 2026-09-09.

7entries
8years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019AdvancedFY2020 – FY2021RestatedFY2022 – FY20252019: 12020: 120202021: 120212022: 120222023: 020232024: 120242025: 120252026: 12026
Same theme, other companies
Expanding R&D personnel and strengthening the development structureA theme 51 companies write about · 0 as a headwind · 52 as a tailwind

The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.

31 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 51 companies compared. The sentences above are computed from all 51.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-09AdvancedShare Issuance and Disposal

    「They will be issued with no payment required in order to secure talented personnel.」

    The grant of stock acquisition rights to 47 executive officers and employees was disclosed for the purpose of securing talented personnel.
  2. FY2025RestatedAnnual report

    「Accordingly, we recognize that developing and acquiring outstanding research personnel to support our original research activities is an urgent management issue for the Company.」

    In response to the acceleration of research and development and intensifying competition, the policy of prioritizing the development and acquisition of outstanding research personnel has been reaffirmed.
  3. FY2024RestatedAnnual report

    「Accordingly, we recognize that developing and acquiring outstanding research personnel to support our original research activities is an urgent management issue for the Company.」

    In response to intensifying competition and the acceleration of research and development, the policy of prioritizing the development and acquisition of outstanding research personnel has been reaffirmed.
  4. FY2022RestatedAnnual report

    「Accordingly, we recognize that developing and acquiring outstanding research personnel to support our original research activities is an urgent management issue for the Company.」

    In response to intensifying competition and the acceleration of research and development, the policy of prioritizing the development and acquisition of research personnel has been reaffirmed.
  5. FY2021AdvancedAnnual report

    「The number of employees increased by 12 from the previous fiscal year, mainly due to an increase in research staff.」

    The number of employees increased by 12 year on year, primarily due to an increase in research staff, indicating progress in securing research personnel.
  6. FY2020AdvancedAnnual report

    「The number of employees increased by 13 from the previous fiscal year, mainly due to an increase in research staff.」

    Progress was reported in securing and expanding research personnel, with the number of employees increasing by 13 year on year, primarily due to an increase in research staff.
  7. FY2019First statedAnnual report

    「Accordingly, we recognize that acquiring outstanding research personnel to support our original research activities is an urgent management issue for the Company.」

    In response to intensifying competition and the acceleration of research and development, the Company identifies the acquisition of outstanding research personnel as an urgent priority.
Moved together

"Increasing incentives to contribute to R&D and auditing through stock options" moved the same way as this thread, in the same document, in 3 of its 7 moves.

32222★12345
  1. ★This thread
  2. 1Increasing incentives to contribute to R&D and auditing through stock options3×
  3. 2Clinical development of HMGB1 peptides for multiple indications2×
  4. 3Strengthening the financial base through funding from capital markets and investors2×
  5. 4Accelerating research and development activities2×
  6. 5A business model centered on out-licensing to pharmaceutical companies following research and development2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for StemRIM yet. It last moved in the Share Issuance and Disposal of 2026-09-09: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.